Munger Mode rating: 3 out of 5 — Hold. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
Which kind of 3★ this is: a wonderful business at a premium. The moat and management are good enough that we would hold it happily if we owned it. At about 27x forward earnings and a 2.6% free cash flow yield, we would not start a new position. Price used: about $680 a share. The only quotes I could verify were $694.55 on the October 21 earnings day and $676.54 in a research note around October 23. I could not verify a close for October 30. Market cap is roughly $252 billion on 370.5 million shares, and enterprise value is roughly $287 billion. Thermo Fisher sells the picks and shovels of modern science and medicine. Its customers are drug and biotech companies, universities and governments, industrial and environmental labs, and hospitals and diagnostics labs.
Recent filings analysed: 10-Q (2026-10-30), 8-K (2026-10-30), 8-K (2026-10-21), 10-Q (2026-07-31).
Stock screener · Superinvestor 13F holdings · Analyst sentiment